← Oncology Approval Tracker

FDA DECISION ·

Bendamustine (Treanda first generics)

bendamustine hydrochloride · Accord Healthcare and Dr. Reddy’s Laboratories

First generic approvalFirst genericChronic lymphocytic leukemia and indolent B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First generic vial products for CLL or indolent B-cell non-Hodgkin lymphoma that progressed during or within six months after rituximab-based treatment.

LAMPGEN ANALYSIS

Why it matters

The approvals add generic powder-for-injection products for established hematology indications.

What research teams should watch

Use product-specific preparation instructions and document prior rituximab timing for the lymphoma indication.

PRIMARY RECORDS

Sources